BusinessAXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS PatientsBy Nasdaq OMXJan 23, 2018, 2:02 PM UTC
BusinessAxim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)By Nasdaq OMXNov 21, 2017, 2:00 PM UTC
BusinessNew U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis TreatmentBy Nasdaq OMXOct 5, 2017, 1:00 PM UTC
BusinessAXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York CityBy Nasdaq OMXSep 7, 2017, 1:00 PM UTC
BusinessAXIM Biotechnologies Reports Second Quarter 2017 ResultsBy Nasdaq OMXAug 22, 2017, 1:01 PM UTC
BusinessAXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg SyndromeBy Nasdaq OMXJul 20, 2017, 1:00 PM UTC
BusinessAXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing GumBy Nasdaq OMXJan 18, 2017, 2:01 PM UTC
BusinessAXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing GumBy Nasdaq OMXJan 18, 2017, 2:01 PM UTC
